Desktop Health™ Introduces the PrintRoll™ Rotating Build Platform for the 3D-Bioplotter® — a First-of-its-kind Bioprinting Tool to Develop Tubular Solutions for Vascular, Digestive, Respiratory, and Other Channels
24.7.2023 15:30:00 EEST | Business Wire | Press release
Desktop Health — the trusted production-grade medical 3D printing brand of Desktop Metal, Inc. (NYSE: DM) — today announced a breakthrough in bioprinting with the launch of PrintRoll™, an innovative rotating build platform that can produce intelligent tubular solutions for the body’s vascular, digestive, respiratory, and reproductive channels on the 3D-Bioplotter premier bioprinting system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724680554/en/
Nicole Black, Ph.D., VP of Biomaterials and Innovation at Desktop Health, examines two tubular medical devices printed on the new 3D-Bioplotter® PrintRoll™ rotating build platform in medical-grade materials. PrintRoll is designed to enable new medical solutions for the body’s thousands of miles of internal channels, such as vascular, digestive, and other systems. (Photo: Business Wire)
The 3D-Bioplotter is a highly sophisticated extrusion-based 3D printer that processes liquids, melts, pastes, gels, or other materials, including cells, through a needle tip on a Swiss-made, 3-axis gantry system with high accuracy and temperature, sterility, and design controls. 3D-Bioplotter offers eight printheads with the widest range of temperatures in bioprinting — from 2°C to 500°C (35.6°F to 932°F) — enabling complex, multi-material medical parts.
The PrintRoll add-on feature has been in development since 2019 as part of a collaboration with Johannes Gutenberg University Mainz, a public research university in Mainz, Germany.
“We are proud to offer the first bioprinting tool specifically designed to develop medical solutions for the thousands of miles of channels found in the human body,” said Ric Fulop, Founder and CEO of Desktop Metal. “Desktop Health exists to deliver 3D printing solutions that improve patient lives, and we are confident that PrintRoll, offered exclusively on the 3D-Bioplotter, will enable all-new regenerative innovations. We look forward to seeing what our customers will create next with this exciting new tool.”
Visit TeamDM.com/3DBioplotterBrochure to see a video of the PrintRoll in action and download the latest 3D-Bioplotter brochure, which chronicles 20+ years of innovations on the bioprinter by regenerative medicine experts.
How PrintRoll Works
The PrintRoll platform attaches to the modular build plate of the 3D-Bioplotter and features a motor-driven rotating mandrel with spring-loaded, easily exchangeable drums of different sizes. Rotating speed is tightly controlled by the 3D-Bioplotter’s easy-to-use software.
As the PrintRoll tool rotates, the printhead moves back and forth depositing material on the surface in the desired design. For example, polycaprolactone (PCL), a medical-grade, biodegradable plastic used in many FDA-cleared implants and devices, hardens quickly on the drum after the melted material is printed. In bioprinting, users typically produce a structure or scaffold in a stiff or flexible biocompatible material that is designed to repair and integrate with cells of the body, sometimes degrading after a certain period of time.
The PrintRoll comes with a 10 mm diameter drum – with 20 mm and 40 mm sizes available – designed to accommodate the development of solutions for a variety of human channels, which vary based on age and gender. Standard diameter sizes generally correspond to the diameters of the femoral artery (~10 mm), trachea (~10-20 mm), fallopian tube (~5-15 mm), aorta (~25 mm) esophagus (~30 mm), and a range of intestine segments (~40-100 mm).
The PrintRoll system supports printing hollow cylindrical structures up to 140 mm in length, depending on the printhead used. Custom sizes may also be available.
“Up until now, the creation of thin-walled cylindrical devices with complex structured walls has been challenging to accomplish with regenerative materials, such as hydrogels,” said Nicole Black, Ph.D., VP of Biomaterials and Innovation at Desktop Health. “With the PrintRoll, materials are patterned directly on top of a substrate that rolls as the printhead also moves, supporting the deposited layers and therefore expanding the palette of materials that can be 3D printed into these important structures. Following printing, devices can be removed from the PrintRoll, leaving high-resolution and reproducible parts that customers have come to expect from the 3D-Bioplotter.”
The PrintRoll comes with a library of honeycomb designs and standard printing parameters for common materials. The PrintRoll platform, which is compatible with 4th Generation 3D-Bioplotter models, is available for pre-order now, with shipping expected in the fourth quarter. Contact Desktop Health to learn more at TeamDM.com/3DBioplotterMoreInfo .
3D-Bioplotter® Continues Pioneering Bioprinting
PrintRoll continues the long history of bioprinting innovations on the world’s most researched bioprinting system, as detailed in the last 3D-Bioplotter brochure.
This tradition is also continued with CMFlex™ — the first 3D printed regenerative bone graft substitute product cleared by the FDA and the first such clearance based on manufacturing on the 3D-Bioplotter. Developed by Dimension Inx, CMFlex is an easy-to-use flexible bone graft product that is 3D printed on a standard 3D-Bioplotter Manufacturer model. This new product is an alternative to an autograft, in which a physician intrusively harvests bone from one area of a patient’s body to repair damaged or diseased bone elsewhere in the body.
“The recent FDA clearance of CMFlex by Dimension Inx is a breakthrough for the field of additive, regenerative medicine – one that clearly showcases the robustness of the 3D-Bioplotter,” said Lou Azzarra, President of Desktop Health. “Commercial milestones like this often take many years, and we congratulate the entire team at Dimension Inx on this achievement.”
Visit TeamDM.com/3DBioplotterBrochure to download our latest brochure, which details how Dimension Inx developed CMFlex for commercialization.
About Desktop Metal
Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products. Our innovative 3D printers, materials, and software deliver the speed, cost, and part quality required for this transformation. We’re the original inventors and world leaders of the 3D printing methods we believe will empower this shift, binder jetting and digital light processing. Today, our systems print metal, polymer, sand and other ceramics, as well as foam and recycled wood. Manufacturers use our technology worldwide to save time and money, reduce waste, increase flexibility, and produce designs that solve the world’s toughest problems and enable once-impossible innovations. Learn more about Desktop Metal and our #TeamDM brands at www.desktopmetal.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
_______________________
1“Hence, 3D Bioplotter® which was capable of cell-laden bioprinting, could be defined as the first commercial 3D bioprinter in the world.” Gu Z, Fu J, Lin H, He Y. Development of 3D bioprinting: From printing methods to biomedical applications. Asian J Pharm Sci. 2020 Sep;15(5):529-557. doi: 10.1016/j.ajps.2019.11.003. Epub 2019 Dec 17. PMID: 33193859; PMCID: PMC7610207. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610207/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724680554/en/
Contact information
Media Relations:
Sarah Webster
sarahwebster@desktopmetal.com
(313) 715-6988
Investor Relations:
Jay Gentzkow
jaygentzkow@desktopmetal.com
(781) 730-2110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 20268.3.2026 10:00:00 EET | Press release
Aqara, a global leader and pioneer in IoT, today unveiled its cutting-edge innovations in intelligent space technology at Light + Building 2026 (Hall 9.0, Booth A50). Aqara’s demonstration offers a glimpse into a comprehensive system that offers intelligent lighting control, energy saving, and space security experience for professional usage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308903989/en/ Aqara Showcases Scaling Professional-Grade Infrastructure and Unified Management at Light + Building 2026 System-level Intelligent Control Aqara introduces a centralized system solution designed to streamline the management of building deployments at any scale. Moving beyond individual device control, Aqara offers a unified solution that provides architects, facility managers, and developers with a single interface to oversee lighting, environmental sensing, and energy consumption across entire floors or multiple properties
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
